Clinical Trials for Kidney Cancer

A Phase 2, Open-label, Multicenter Study of IBI363 (PD1-IL2m) in Subjects with Advanced Solid Malignancies

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial involves adult patients with advanced solid tumors who have limited treatment options, evaluating the efficacy and safety of IBI363, a PD-1/IL-2α-bias bispecific antibody fusion protein targeting the PD-1/PD-L1 pathway and activating the IL-2 pathway to enhance tumor-specific T cell activity.

ClinicalTrials.gov ID: NCT06281678

Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic/advanced clear cell RCC who progressed after at least one systemic line including a PD-1/PD-L1 inhibitor (two cohorts based on prior VEGF/HIF-2α exposure) receive ivonescimab monotherapy IV q3w. Ivonescimab is a bispecific PD-1/VEGF antibody designed to simultaneously restore antitumor immunity and inhibit angiogenesis.

ClinicalTrials.gov ID: NCT06940518

EXACT: Randomized Phase II Trial of XL092 in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with advanced/metastatic clear cell RCC who progressed on or after adjuvant anti–PD-1/PD-L1 therapy (no prior systemic therapy otherwise) are randomized to zanzalintinib (XL092), an oral multi-targeted TKI of VEGFR2/MET/TAM kinases, versus XL092 plus nivolumab (PD-1 inhibitor). Key exclusions include untreated/unstable CNS mets and active autoimmune disease requiring immunosuppression.

ClinicalTrials.gov ID: NCT06863311

A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable or metastatic clear cell RCC who progressed on prior PD‑1/PD‑L1 therapy are randomized to casdatifan (AB521, a selective allosteric HIF‑2α inhibitor) plus cabozantinib versus cabozantinib plus placebo. Excludes prior HIF‑2α inhibitor or cabozantinib exposure; key goal is to improve PFS with the HIF‑2α/VEGFR–TKI combination.

ClinicalTrials.gov ID: NCT07011719

A Randomized Phase 2 Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with previously untreated advanced/unresectable or metastatic clear cell RCC (all IMDC risk groups; KPS ≥70; measurable disease) are randomized to fianlimab (anti–LAG-3) plus cemiplimab (PD-1 inhibitor) with or without ipilimumab (CTLA-4 inhibitor) versus standard ipilimumab plus nivolumab (PD-1 inhibitor, with nivolumab maintenance). The trial evaluates ORR and safety of LAG-3/PD-1 dual blockade (± CTLA-4) as first-line immunotherapy in this population.

ClinicalTrials.gov ID: NCT07188896

A Phase 2 Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma - SPARCC

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Single-arm study for treatment-naïve adults with measurable unresectable advanced or metastatic RCC with clear cell component, including sarcomatoid features, or defined translocation RCC, ECOG 0–2. Patients receive sasanlimab, an anti–PD-1 antibody, plus palbociclib, an oral CDK4/6 inhibitor, and axitinib, an oral VEGFR TKI.

ClinicalTrials.gov ID: NCT07123090

A Randomized Phase II Trial of Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Oligo-Metastatic Clear Cell Renal Cell Carcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with oligometastatic clear cell renal cell carcinoma with 1–5 RECIST-measurable lesions amenable to definitive SBRT, including the primary tumor if present, receive SBRT to all disease sites and are then randomized to cemiplimab, an anti–PD-1 antibody, with or without fianlimab, an anti–LAG-3 antibody. Treatment is given every 3 weeks for up to 1 year to test whether dual checkpoint blockade improves 1-year progression-free survival after SBRT.

ClinicalTrials.gov ID: NCT07223541

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: The trial investigates APL-101, a selective c-MET receptor tyrosine kinase inhibitor, in adult patients with NSCLC exhibiting c-Met exon 14 skipping mutations, various solid tumors with MET alterations, and primary CNS tumors. It includes APL-101 monotherapy and combination therapy with EGFR inhibitors in cases of acquired MET amplification resistance.

ClinicalTrials.gov ID: NCT03175224

Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults and children with biopsy-proven EBV-positive PTLD after solid organ or allogeneic HCT who have failed rituximab (± chemotherapy for SOT) receive tabelecleucel, an allogeneic, off‑the‑shelf EBV‑specific cytotoxic T‑cell therapy matched by HLA and infused on days 1, 8, and 15 of 35‑day cycles. Excludes T‑cell lymphomas, active/untreated CNS PTLD, significant GVHD, recent checkpoint inhibitors or EBV‑directed cell therapies, and requires measurable FDG‑avid disease and adequate organ function.

ClinicalTrials.gov ID: NCT03394365

STING Agonist and Personalized Ultra-fractionated Stereotactic Adaptive Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer (SPARK)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic clear-cell RCC showing oligoprogression (1–3 lesions) after prior anti–PD-1/CTLA-4 therapy receive continued nivolumab plus PULSAR stereotactic adaptive radiotherapy to all progressing sites, with one lesion also injected intratumorally with the STING agonist IMSA101 (2′3′-cGAMP analog activating TMEM173 to induce type I IFNs) over five doses. Requires at least one safely injectable non-lung lesion; excludes progressive ultracentral/central chest lesions.

ClinicalTrials.gov ID: NCT06601296